Table 3 Sarilumab-related adverse events (62 patients)
Adverse event | n (%) | Mild, n (%) | Moderate, n (%) | Sarilumab discontinuation n (%) |
|---|---|---|---|---|
Hepatotoxicity | 6 (9.7) | 5 (8.1) | 1 (1.6) | 0 |
Infections | 4 (6.5) | 1 (1.6) | 3 (4.9) | 0 |
Hypersensitivity/Intolerance | 8 (12.9) | 2 (3.2) | 6 (9.7) | 7 (11.9) |
Gastrointestinal | 0 (0) | 0 (0) | 0 (0) | 0 |
Hematological, total Neutropenia (n = 22) Thrombocytopenia (n = 2) | 24 (38.7) | 11 (17.7) | 13 (20.9) | 5 (8.1) |
Dyslipidemia | 18 (29) |